We have recently shown the in vivo anti-obesity effects of sodium tungstate. In this study, we investigate the in vitro effects of sodium tungstate on adipocyte differentiation and function. Methods: 3T3-F442A cells were allowed to differentiate in the presence of sodium tungstate, and were analyzed for triglyceride (TG) accumulation, adipocyte differentiation and mitochondrial oxygen consumption. Results: Sodium tungstate treatment of adipose cells decreased TG accumulation and adipocyte differentiation. Expression of key genes for adipocyte function (aP2, ACC, fatty acid synthase (FAS) and lipoprotein lipase (LPL)) and differentiation (CCAAT enhancer-binding protein (C/EBP)a and peroxisome proliferator-activated receptor gamma (PPARg)) was reduced by sodium tungstate, whereas C/EBPb isoform LIP expression level was increased. TG accumulation and changes in C/EBPb expression were partially recovered by inactivating the erk1/2 pathway. Finally, tungstate treatment increased the oxygen consumption of adipose cells without changes in the expression of oxidative genes. Conclusions: Sodium tungstate inhibits adipocyte differentiation by promoting the translation of LIP, a master dominantnegative regulator of this process, and regulates the mitochondrial oxygen consumption of adipose cells. These effects contribute to the anti-obesity activity of sodium tungstate and confirm its potential as a powerful alternative for the treatment of obesity.
Introduction
Obesity has become a major health problem in many Western and developing countries, especially because of its associated co-morbidities. 1 Effective prevention programs and treatments for obesity still need to be developed. One of the main promising drugs recently tested is sodium tungstate. 2 We and others have shown its effectiveness in improving the different aspects of metabolic diseases. On the one hand, sodium tungstate is a well-known antidiabetic agent in streptozotocin and Zucker diabetic rats, mainly because it restores hepatic glucose metabolism and regenerates pancreatic b-cell population. [3] [4] [5] On the other hand, it emerges as a new anti-obesity drug, because of its effects on energy dissipation. Thus, it enhances thermogenesis in the brown adipose tissue and lipid oxidation in the white adipose tissue of diet-induced obese animals. 2 Proteomic approaches have identified different targets of sodium tungstate in both white and brown adipose tissues, most of which are related to energy dissipation, lipid and carbohydrate metabolism, and redox systems. 6, 7 Adipose tissue development implies a genetic program of activation of transcription factors. 8 Two families of proteins play a major role in this process. Activation of CCAAT enhancer-binding proteins b and d (C/EBPb and d), leads to the induction of the key adipogenic factors C/EBPa and peroxisome proliferator-activated receptor gamma (PPARg), which in turn induce the expression of the adipose marker genes, such as aP2, lipoprotein lipase (LPL) or fatty acid synthase (FAS). 9 Inhibition of adipocyte differentiation can be achieved by modulating the activity of these proteins. For instance, phosphorylation of PPARg inhibits adipocyte differentiation. 10 Differential translation of C/EBPb can be another mechanism to modulate adipocyte differentiation. Two C/EBPb isoforms, translated from the same mRNA, have been described to have opposite roles: LAP, liver-enriched activated protein, enhances adipocyte differentiation, whereas liver-enriched inhibitory protein (LIP) blocks the process by acting as a dominant-negative factor of the other C/EBPs. 11 The differential translation of both isoforms is tightly regulated by the activity of mRNA binding proteins (that is, CUGBP1) 12 which in turn can be modulated by other events, such as phosphorylation. 13 Further adipose tissue development needs the accumulation of lipids either by the induction of lipid synthesis or by lipid uptake. All these processes are energy-consuming pathways, highlighting the importance of a well-developed mitochondrial system to provide adenosine triphosphate. Excessive lipid synthesis and uptake or deficient energy consuming systems may favor the development of hypertrophic adipocytes, enlargement of adipose tissue depots and, finally, obesity.
The role of mitochondria in white adipose tissue has been highlighted through recent discoveries. Mitochondrial content increases during adipocyte differentiation, 14 and deficient mitochondrial systems have been described in the adipose tissue of diabetic db/db mice. 15 Indeed, chemical inhibition of mitochondrial function exacerbates lipid accumulation in adipocytes. 16 In this report we describe the in vitro effects of sodium tungstate on adipocyte differentiation and mitochondrial function, identifying C/EBPb and mitochondria as effectors of sodium tungstate in adipose cells.
Materials and methods
Cell culture and treatments 3T3-F442A cells were grown as described earlier, 17 with some modifications. In brief, the cells were grown to confluence in Dulbecco's modified Eagle's medium (DMEM) supplemented with 10% fetal calf serum (FCS) and 1% antibiotics (streptomycin, penicillin, and amphotericyn). At this time point, the medium was changed every other day and supplemented or not either with insulin (50 nM) or with rosiglitazone (50 nM) with or without sodium tungstate at the indicated concentrations (from 1 to 100 mM). When kinase inhibitors were used, cells were treated, either for seven days or acutely after confluence, with PD 98059, U0126 or SB 202190 at the indicated concentrations. The cells were washed with PBS, resuspended and counted before being processed either for triglyceride quantification, RNA or protein isolation, or for measurement of cellular respiration. Protein isolation and western blot. Cells were scrapped, lysed and homogenized in a buffer containing 50 mM Tris-HCl (pH 7.5), 150 mM NaCl, 1% (v/v) Triton X-100, phosphatase inhibitors (10 mM sodium phosphate, 10 mM sodium fluoride and 1 mM sodium orthovanadate) and protease inhibitor mixture (Sigma, St. Louis, MO, USA). Proteins were quantified, separated in a 12% acrylamide gel and transferred to polyvinylidine fluoride (PVDF) membranes. Membranes were stained with ponceau to verify the amount of loaded protein. An antibody against C/EBPb (C-19, Santa Cruz Biotechnology, Inc., Santa Cruz, CA, USA) was used to detect both the isoforms of the protein. Membranes were stripped and reproved with an antiphospho-p42/p44 MAPK antibody (Cell Signaling Technology, Inc., MA, USA).
Triglyceride quantification
Protein oxidation. Protein oxidation was assessed as described earelier 7 using the OxyBlot protein oxidation detection kit (Chemicon, Temecula, CA, USA). In brief, sodium dodecyl Measurement of cellular respiration. Cellular respiration was measured using the Oroboros oxygraph as described earlier. 18 In brief, 3T3-F442A cells were resuspended in DMEM medium, and 10 6 cells were used for measurements of basal respiration. After observing steady-state respiratory flux, adenosine triphosphate synthase was inhibited with oligomycin (0.25-0.5 mg l -1
), and the cells were titrated with the uncoupler carbonyl cyanide 3-chloro-phenylhydrazone (CCCP) up to optimum concentrations in the range of 1-2 mM. Complex I activity was blocked by the addition of Rotenone (2-4 mM). Finally, mitochondrial oxygen consumption was stopped with the Complex III inhibitor, antimycin A (10 mM).
Results
Sodium tungstate decreases triglyceride accumulation in 3T3-F442A cells 3T3-F442A cells were grown and allowed to differentiate in the presence of sodium tungstate (W) at different concentrations. No differences between untreated and treated cells were observed regarding cell number (1.18 ± 0.05 and 1.15 ± 0.06 million cells per plate, respectively), indicating that sodium tungstate treatment did not influence proliferation or viability of the cells. Sodium tungstate decreased TG accumulation in a dose-dependent manner (Figure 1a) . At 100 mM, sodium tungstate attained its maximal effect on TG accumulation; therefore this concentration was chosen for the following experiments. Cells were treated with either insulin or rosiglitazone, two potent adipogenic stimulators. In these conditions, sodium tungstate treatment still decreased TG accumulation (Figure 1b) . To find out whether sodium tungstate's effects on TG accumulation were dependent on the starting and duration times of the treatment, the cells were treated with sodium tungstate from day 0 (confluence) to day 3, from day 3 to 5, or from day 5 to 7, and TG accumulation was measured at day 7. Sodium tungstate decreases TG content at day 7 independently of the starting time of the traatment (Figure 1c) . These results suggested that sodium tungstate could inhibit adipocyte differentiation in a hormone-and time-independent manner.
Sodium tungstate inhibits the gene expression of adipocyte differentiation profile in 3T3-F442A cells Real-time PCR was carried out to analyze adipogenic gene expression. After 7 days of tungstate-treatment, the mRNA expression of the adipogenic markers, LPL, aP2, ACC1 and FAS was importantly reduced (Figure 1d ), even when cells were stimulated with insulin or rosiglitazone (data not shown). Furthermore, the mRNA expression profile of the key transcription factors involved in adipogenesis was dramatically altered (Figure 1e) . Thus, whereas C/EBPa and PPARg 2 -mRNA expression was decreased, the expression of C/EBPb-mRNA was increased and that of C/EBPd remained unchanged. These data show that sodium tungstate decreases TG accumulation in part by inhibiting adipocyte differentiation.
Sodium tungstate does not alter protein oxidation in 3T3-F442A cells Tungstate can modulate the oxidation states of different systems. In fact, it has been classically used as an oxidizing agent in organic chemistry 19, 20 and may act as a co-factor activating or inhibiting some oxidizing enzymes. [21] [22] [23] In vivo, sodium tungstate decreases the oxidation state of brown adipose tissue proteins and modulates several redox proteins both in white and brown adipose tissues. 6, 7 In order to assess whether sodium tungstate modulates the redox state of our system, we performed oxidation assays of proteins from 3T3-F442A cells chronically treated with sodium tungstate. As shown in Figure 1f , sodium tungstate did not modify the protein oxidation state of the cells.
Sodium tungstate changes the ratio between C/EBPb-LAP and C/EBPb-LIP As C/EBPb acts a master regulator of adipogenesis either by stimulating or by repressing it, because of the differential expression of its isoforms LAP and LIP, we analyzed whether the ratio between these two proteins was changed in tungstatetreated cells. As shown in Figure 2a and b, sodium tungstate treatment increased the expression of both LAP and LIP, in accordance with the increased mRNA expression of C/EBPb. However, this increase was even higher for LIP, thus changing the ratio between both isoforms (Figure 2c ). Indeed, LIP represented 45% of the total C/EBPb protein in the tungstatetreated cells, as against just 30% in control cells (Figure 2d ).
Sodium tungstate decreases TG accumulation through the erk1/2 pathway
As a well-known phosphatase inhibitor, sodium tungstate could mediate its effects on adipocytes by increasing the phosphorylation state of some kinases. To determine the putative kinases involved in its effects, cells were treated chronically with specific erk1/2 (PD 98059, U 0126) or p38 (SB 202190) kinase inhibitors. Only when cells were treated with the specific erk1/2 inhibitors PD 98059 or U 0126 did sodium tungstate lose its ability to decrease TG accumulation (Figure 3a) . No effect was observed either with the specific p38 inhibitor, SB 202190 (Figure 3b) , or with the inhibitor of the PKB-Akt pathway wortmannin (data not shown).
Dual effects of tungstate on adipocyte biology MC Carmona et al
Sodium tungstate changes C/EBPb isoform expression through erk1/2 activation Sodium tungstate increased the phosphorylation state of erk1/2 in preadipocytes as fast as within 1-5 min after tungstate treatment (Figure 3c ), but did not change the phosphorylation state of p38 (data not shown). This effect was blocked by the specific erk1/2 inhibitor, U 0126, which also prevented the rise in LAP and LIP isoforms caused by sodium tungstate treatment.
Sodium tungstate increases cellular oxygen consumption without changes in mitochondrial gene expression In vivo, sodium tungstate induces energy expenditure mainly by increasing oxidative gene expression. 2 In vitro, cells that were treated with sodium tungstate for 7 days increased basal oxygen consumption as well as augmented oligomycin and carbonyl cyanide 3-chloro-phenylhydrazone (CCCP)-dependent respiration compared with untreated cells (Figure 4a ). These effects reflected the increase in both coupled and uncoupled respiration (Figure 4b) . Surprisingly, when mRNA expression of key oxidative genes was analyzed, no differences were found between tungstate-treated and untreated cells (Figure 4c ).
Discussion
In this study we show the potential effects of sodium tungstate on adipocyte differentiation and function. Thus, Dual effects of tungstate on adipocyte biology MC Carmona et al tungstate treatment of adipose cells blocks adipocyte differentiation and increases energy consumption, in total accordance with the earlier in vivo results in which tungstate decreased fat mass, mainly by inhibiting differentiation and increasing energy dissipation.
2,6,7
In vitro, adipocyte differentiation is blocked by tungstate, independently of hormone treatment. Both insulin and rosiglitazone, commonly used for the treatment of type 2 diabetes in different degrees, increase adipose mass in vivo and adipocyte differentiation in vitro. 24, 25 The fact that tungstate counteracts these effects could be seen as a potential mechanism to moderate these side effects. Furthermore, taking into account the antidiabetic effects of sodium tungstate enhancing insulin sensitivity in the liver and muscle, 3, 4, 26 it is tempting to speculate a favorable interaction with either insulin or rosiglitazone treatment in vivo.
In view of our results, we propose a dual mechanism of action of sodium tungstate. On the one hand, it preferentially activates the translation of a master dominant-negative regulator of adipocyte differentiation, LIP. A complex regulation of C/EBPb expression that is highly dependent on the activity of mRNA-binding proteins, such as CUGBP1 12,27,28. In fact, CUGBP1 binding to the 5 0 -untranslated region of the C/EBPb-mRNA is necessary to increase LIP translation and hence to decrease adipocyte differentiation. 29 Furthermore, CUGBP1 activity depends on its phosphorylation state. 13, 28, 30 Knowing that sodium tungstate is a potent phosphatase inhibitor, 31 we could imagine a cascade of action of tungstate in which it promotes erk1/2 activity, phosphorylation of CUGBP1, differential expression of LIP and inhibition of adipogenesis. Whether CUGBP1 is directly involved in this cascade must be verified in future experiments.
On the other hand, sodium tungstate increases oxygen consumption of adipose cells, independently of changes in the mRNA expression of key oxidative genes (PPARa, M-CPT1, MCAD, COI and UCP2). Increasing reports over the past few years suggest a direct regulation of mitochondrial activity by phosphorylation events in several cell types, in which some classical cytosolic kinases are found in mitochondria [32] [33] [34] [35] acting on different subunits of the respiratory chain complexes. [36] [37] [38] [39] [40] [41] We cannot exclude a direct Dual effects of tungstate on adipocyte biology MC Carmona et al
